Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 634-636

  Santoro, Vincenza ^a   D'Arrigo, Concetta ^a   Spina, Edoardo ^a   Micò, Umberto ^a   Muscatello, Maria R ^a   Zoccali, Rocco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CLOZAPINE; DULOXETINE; NORCLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYNDROME; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; VERTIGO;

ADULT; BENZODIAZEPINES; CLOZAPINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISPERIDONE; THIOPHENES; YOUNG ADULT;

EID: 77957288765     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181ee2afe     Document Type: Letter

References (13)

1. Conley RR, Ascher-Svanum H, Zhu B, et al. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90: 186-197. (Pubitemid 46177554)
2. Englisch S, Knopf U, Scharnholz B, et al. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial. J Psychopharmacol. 2009;23: 875-882.
3. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73: 170-177. (Pubitemid 36269668)
4. Cymbalta\(duloxetine hydrochloride) delayed-release capsule prescribing information. Indianapolis, IND: Eli Lilly and Company 2007.
5. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30: 1206-1227.
6. Raggi MA, Mandrioli R, Sabbioni C, et al. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological implications. Curr Med Chem. 2004;11: 279-296. (Pubitemid 38240208)
7. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100: 4-22. (Pubitemid 46051438)
8. Avenoso A, Facciolà G, Campo GM, et al. Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl. 1998;714: 299-308. (Pubitemid 28386852)
9. Darrigo C, Migliardi G, Santoro V, et al. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 2006;28: 388-393. (Pubitemid 44314927)
10. Avenoso A, Facciolà G, Salemi M, et al. Determination of risperidone and its major metabolite 9-hydroxy-risperidone in human plasma by reversed phase liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl. 2000;746: 173-181.
11. Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27: 28-34. (Pubitemid 46105760)
12. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002;22: 419-423. (Pubitemid 34810333)
13. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23: 223-227. (Pubitemid 32476548)